Amgen seeks approval for myeloma drug Kyprolis in US and Europe
Kyprolis is currently indicated in the US to treat patients with relapsed multiple myeloma who have received at least two other treatments. The sNDA is designed to support
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule therapeutics targeting a G protein-coupled receptor (GPCR).
The randomized double-blind, event-driven superiority trial is designed to examine the benefits of the once-daily, oral Factor Xa Inhibitor, rivaroxaban in these patients. Around 7,000 patients will be
The agreement establishes the collaboration and structure to enable better scientific understanding of the medicinal use of cannabis to treat diseases such as Parkinson’s, epilepsy, Alzheimer’s, brain damage,
The expanded agreements will allow Gilead’s India-based partners to manufacture GS-5816 and the single tablet regimen of sofosbuvir/GS-5816, once approved, for distribution in 91 developing countries, which together